Fate Therapeutics
ISIN US31189P1021
|WKN A1W50M
Market cap (in EUR)
100 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 100 m |
| EPS, EUR | -1.19 |
| P/B ratio | 0.5 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 13 m |
| Net income, EUR | -172 m |
| Profit margin | -1,366.46% |
What ETF is Fate Therapeutics in?
There is 1 ETF which contains Fate Therapeutics.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.01% | Equity United States Health Care Biotech | 44 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.